Sanofi and Regeneron hosted a conference call for the financial community on the Praluent® FDA approval in the U.S.

  • Presentation
  • Press release: Sanofi and Regeneron Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients